. 2017 Aug 11;8(39):66458–66466. doi: 10.18632/oncotarget.20185

Table 1. Characteristics of studies included for meta-analysis of OS including patient population, treatment arms, and effect estimates (HRs along with 95% confidence intervals and sample sizes for comparator groups) for subgroups defined by all-RAS, KRAS, or BRAF mutation status.

Trial	Treatments (N)	*All–RAS* WT**	*Any RAS* MT**	KRAS WT	KRAS MT	*BRAF*^c WT	*BRAF*^c MT
CRYSTAL [6, 18]	FOLFIRI + cetuximab (599)	0.69 (0.54–0.88) 178:189	1.05 (0.86–1.28) 246:214	0.80 (0.67–0.95) 316:350	1.03 (0.83–1.28) 214:183	0.70 (0.54–0.91) 156:159	–
CRYSTAL [6, 18]	FOLFIRI^a (599)	0.69 (0.54–0.88) 178:189	1.05 (0.86–1.28) 246:214	0.80 (0.67–0.95) 316:350	1.03 (0.83–1.28) 214:183	0.70 (0.54–0.91) 156:159	–
OPUS [19, 20]	FOLFOX + cetuximab (169)	0.94 (0.56–1.56) 38:49	1.29 (0.91–1.84) 92:75	0.85 (0.60–1.22) 82:97	1.29 (0.87–1.91) 77:59	0.95 (0.55–1.64) 34:45	–
OPUS [19, 20]	FOLFOX^a (168)	0.94 (0.56–1.56) 38:49	1.29 (0.91–1.84) 92:75	0.85 (0.60–1.22) 82:97	1.29 (0.87–1.91) 77:59	0.95 (0.55–1.64) 34:45	–
FIRE-3 [21, 22]	FOLFIRI + cetuximab (297)	0.70 (0.54–0.90) 199:201	–	0.77 (0.62–0.96) 297:295	–	–	–
FIRE-3 [21, 22]	FOLFIRI + bevacizumab^a (295)	0.70 (0.54–0.90) 199:201	–	0.77 (0.62–0.96) 297:295	–	–	–
PEAK [23]	FOLFOX + panitumumab (142)	0.63 (0.39–1.02) 88:82	–	0.62 (0.44–0.89) 142:143	–	–	–
PEAK [23]	FOLFOX + bevacizumab^a (143)	0.63 (0.39–1.02) 88:82	–	0.62 (0.44–0.89) 142:143	–	–	–
PRIME [8, 24]	FOLFOX + panitumumab (546)	0.78 (0.62–0.99) 259:253	1.25 (1.02–1.55) 272:276	0.88 (0.73–1.06) 325:331	1.17 (0.95–1.45) 221:219	0.74 (0.57–0.96) 228:218	0.90 (0.46–1.76) 24:29
PRIME [8, 24]	FOLFOX^a (550)	0.78 (0.62–0.99) 259:253	1.25 (1.02–1.55) 272:276	0.88 (0.73–1.06) 325:331	1.17 (0.95–1.45) 221:219	0.74 (0.57–0.96) 228:218	0.90 (0.46–1.76) 24:29
CECOG/ CORE1.2.001 [25]	FOLFOX + cetuximab (77)	–	–	0.48^d (0.26–0.90) 34:23		–
CECOG/ CORE1.2.001 [25]	FOLFIRI + cetuximab (74)	–	–	0.74^d (0.39–1.40) 28:32		–
AIO KRK 0306 [26]	FOLFIRI + cetuximab (50)	–	–	–	0.86 (0.55–1.35) 50:46	–	–
AIO KRK 0306 [26]	FOLFIRI + bevacizumab^a (46)	–	–	–	0.86 (0.55–1.35) 50:46	–	–
CALGB-SWOG 80405 [15]	Chemotherapy^b + cetuximab (578)	0.88^e (0.72–1.08) 270:256	–	0.88^f (0.77–1.01) 578:559	–	–	–
CALGB-SWOG 80405 [15]	Chemotherapy^b + bevacizumab^a (559)	0.88^e (0.72–1.08) 270:256	–	0.88^f (0.77–1.01) 578:559	–	–	–
TAILOR [27]	FOLFOX + cetuximab (193)	0.76 (0.61–0.96) 193:200	–	–	–	–	–
TAILOR [27]	FOLFOX^a (200)	0.76 (0.61–0.96) 193:200	–	–	–	–	–

^aReference arm; ^bFOLFOX or FOLFIRI; ^cBRAF evaluated within RAS WT subgroup; ^dThe reported HR is for WT compared to MT for each arm; ^eFor FOLFOX and FOLFIRI, the respective HRs are 0.86 (95% CI 0.6–1.1) 198:192 and 1.1 (95% CI 0.7–1.6) 72:64; ^fFor FOLFOX and FOLFIRI, the respective HRs are 0.83 (95% CI 0.71–0.98) 426:409 and 1.04 (95% CI 0.79–1.35) 152:150.